148 related articles for article (PubMed ID: 8193351)
1. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.
Shpall EJ; Stemmer SM; Hami L; Franklin WA; Shaw L; Bonner HS; Bearman SI; Peters WP; Bast RC; McCulloch W
Blood; 1994 Jun; 83(11):3132-7. PubMed ID: 8193351
[TBL] [Abstract][Full Text] [Related]
2. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
Shpall EJ; Stemmer SM; Bearman SI; Myers S; Purdy M; Jones RB
Breast Cancer Res Treat; 1993; 26 Suppl():S19-23. PubMed ID: 7691269
[TBL] [Abstract][Full Text] [Related]
3. Use of amifostine in bone marrow purging.
Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
[TBL] [Abstract][Full Text] [Related]
4. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
Shpall EJ; Jones RB; Bast RC; Rosner GL; Vandermark R; Ross M; Affronti ML; Johnston C; Eggleston S; Tepperburg M
J Clin Oncol; 1991 Jan; 9(1):85-93. PubMed ID: 1985173
[TBL] [Abstract][Full Text] [Related]
5. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
[TBL] [Abstract][Full Text] [Related]
6. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Carlo-Stella C; Mangoni L; Almici C; Cottafavi L; Meloni G; Mandelli F; Rizzoli V
Blood; 1992 Nov; 80(9):2412-8. PubMed ID: 1421413
[TBL] [Abstract][Full Text] [Related]
7. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Douay L; Hu C; Giarratana MC; Gorin NC
Eur J Cancer; 1995; 31A Suppl 1():S14-6. PubMed ID: 7577094
[TBL] [Abstract][Full Text] [Related]
8. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
9. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
Rowley SD; Piantadosi S; Marcellus DC; Jones RJ; Davidson NE; Davis JM; Kennedy J; Wiley JM; Wingard JR; Yeager AM
Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
[TBL] [Abstract][Full Text] [Related]
10. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia.
Miller CB; Rowlings PA; Zhang MJ; Jones RJ; Piantadosi S; Keating A; Armitage JO; Calderwood S; Harris RE; Klein JP; Lazarus HM; Linker CA; Sobocinski KA; Weisdorf D; Horowitz MM
Exp Hematol; 2001 Nov; 29(11):1336-46. PubMed ID: 11698130
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
12. The potential role of amifostine (Ethyol) in haematological malignancies.
Gorin NC
Eur J Cancer; 1996; 32A Suppl 4():S31-9. PubMed ID: 8976820
[TBL] [Abstract][Full Text] [Related]
13. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.
Chao NJ; Stein AS; Long GD; Negrin RS; Amylon MD; Wong RM; Forman SJ; Blume KG
Blood; 1993 Jan; 81(2):319-23. PubMed ID: 8422458
[TBL] [Abstract][Full Text] [Related]
14. Purging with 4-hydroperoxycyclophosphamide.
Jones RJ
J Hematother; 1992; 1(4):343-8. PubMed ID: 1345676
[TBL] [Abstract][Full Text] [Related]
15. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
Reece DE; Barnett MJ; Connors JM; Klingemann HG; O'Reilly SE; Shepherd JD; Sutherland HJ; Phillips GL
Bone Marrow Transplant; 1993 Feb; 11(2):139-46. PubMed ID: 8435663
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia.
Rowley SD; Jones RJ; Piantadosi S; Braine HG; Colvin OM; Davis J; Saral R; Sharkis S; Wingard J; Yeager AM
Blood; 1989 Jul; 74(1):501-6. PubMed ID: 2665843
[TBL] [Abstract][Full Text] [Related]
18. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
[TBL] [Abstract][Full Text] [Related]
19. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia.
Damon LE; Rugo HS; Ries CA; Linker CA
Bone Marrow Transplant; 1996 Jan; 17(1):93-9. PubMed ID: 8673063
[TBL] [Abstract][Full Text] [Related]
20. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow for acute lymphoblastic leukemia.
Gonzales-Chambers R; Przepiorka D; Shadduck RK; Borochovitz D; Bloom EJ; Colvin OM; Mangan KF; Rosenfeld CS
Med Pediatr Oncol; 1991; 19(3):160-4. PubMed ID: 2023563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]